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The  increasing  demand  for  healthcare  and the  resulting  pressure  on  available  budgets  render  priority
setting  inevitable.  If societies  aim to improve  health  and  distribute  health(care)  fairly,  equity-efﬁciency
trade-offs  are  necessary.  In the  Netherlands,  proportional  shortfall  (PS)  was  introduced  to  quantify  neces-
sity of  care,  allowing  a direct  equity-efﬁciency  trade-off.  This  study  describes  the  history  and  application
of  PS in  the  Netherlands  and  examines  the theoretical  and empirical  support  for  PS as  well  as  its  current
role  in  healthcare  decision  making.  We  reviewed  the  international  literature  on  PS  from  2001  onwards,
along  with  publicly  accessible  meeting  reports  from  the  Dutch  appraisal  committee,  Adviescommissie
Pakket  (ACP),  from  2013  to 2016.  Our  results  indicate  that  there  is support  for  the  decision  model  in  which
necessity  is quantiﬁed  and  incremental  cost-effectiveness  ratios  are  evaluated  against  associated  mone-
tary reference  values.  The  model  enables  a uniform  framework  for priority  setting  across  all  healthcareesource allocation sectors.  Although  consensus  about  the  application  of PS  has  not  yet  been  reached  and  alternative  ways  to
quantify necessity  were  found  in ACP  reports,  PS has  increasingly  been  applied  in  decision  making  since
2015.  However,  empirical  support  for  PS is limited  and  it may  insufﬁciently  reﬂect societal  preferences
regarding  age  and reducing  lifetime-health  inequalities.  Hence,  further  investigation  into  reﬁning  PS—or
exploration  of  another  approach—appears  warranted  for operationalising  the  equity-efﬁciency  trade-off.
© 2018  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND. Introduction
The demand for healthcare is rapidly increasing for reasons
hat include ageing populations and the availability of increasingly
dvanced and expensive (new) health technologies. As healthcare
esources remain scarce, the resulting pressure on available bud-
ets renders healthcare priority setting inevitable [1,2]. Although
olitically and societally sensitive, the need for prioritisation is
idely recognised and explicitly addressing priority setting has
ecome indispensable for developing fairer methods for resource
llocation in healthcare [3,4].
Economic evaluations of health technologies are often used
o inform decision makers regarding how to allocate healthcarePlease cite this article in press as: Reckers-Droog VT, et al. Looking back
in healthcare priority setting in the Netherlands. Health Policy (2018)
esources in an optimal way for society. However, the outcomes
f economic evaluations only predict such decisions to a moderate
xtent [3,5,6]. One explanation for this disparity is that decision
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168-8510/© 2018 The Authors. Published by Elsevier B.V. This is an open access article 
/).license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
makers are not exclusively concerned with maximising health
given available budgets, but also with distributing health(care)
equitably and fairly [3,5,7,8]. Hence, an optimal allocation of
resources involves setting priorities that contribute to both efﬁ-
ciency and equity in the distribution of health(care) [9]. Recognising
that these are both important objectives of healthcare systems, it
has been advocated that societal concerns for equity be explicitly
and transparently incorporated into the decision-making frame-
work [10–12].
In economic evaluations, the value of a health technology is
commonly expressed in terms of an incremental cost per quality-
adjusted life-year (QALY) ratio (ICER) that is evaluated against
some monetary threshold value per QALY gained [3,13–15]. When
the ICER is below this threshold, a health technology is consid-
ered cost-effective and eligible for reimbursement [16]. The classic
approach in the economic-evaluation framework is to value QALY
gains equally, i.e. to adhere to the principle that “a QALY is a QALY
is a QALY”, regardless of beneﬁciary and health technology charac- and moving forward: On the application of proportional shortfall
, https://doi.org/10.1016/j.healthpol.2018.04.001
teristics [17]. However, this approach has been highly debated as it
relies on the assumption of distributive neutrality [3]. In response
to this debate, two  general approaches have been suggested for
operationalising the equity-efﬁciency trade-off [3,5]. One of these
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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pproaches applies equity weights to QALY gains and evaluates
he adjusted ICER against a ﬁxed monetary threshold value, and
he other evaluates an unadjusted ICER against a ﬂexible mon-
tary threshold value [3,5,16]. Ideally, the operationalisation of
he equity-efﬁciency trade-off is both normatively justiﬁable and
mpirically supported. However, this proves to be neither easy nor
traightforward [3,18].
In relation to the operationalisation of the equity-efﬁciency
rade-off, the severity of illness (SOI) and fair innings (FI) equity
pproaches have attracted much attention internationally. Accord-
ng to the normative theories about distributive justice that
nderlie these approaches, priority should be given to those
ho are worse off in terms of health [11,19,20]. However, the
pproaches are based on different normative arguments with
egard to whom is considered worse off, and hence differ with
egard to how they are operationalised [3,19]. A common oper-
tionalisation of SOI aims to equalise absolute health beneﬁts in
erms of current and prospective health, while FI aims to do so
n terms of lifetime health [3,10,11,19]. As such, FI also consid-
rs past health [11,19]. Although both SOI and FI are to some
xtent normatively justiﬁable and empirically supported, neither
f these approaches appears to satisfactorily reﬂect societal prefer-
nces for equity [3,5,7]. Nonetheless, different countries have either
mplicitly or explicitly developed normative principles or guide-
ines that include (aspects of) SOI or FI for informing allocation
ecisions in healthcare [3,5,7]. For example, in the United Kingdom
UK), the National Institute for Health and Care Excellence (NICE)
ormalised the SOI approach by launching guidelines for prioritis-
ng end-of-life care [21,22], and in Norway, the SOI approach is
urrently formalised in terms of absolute shortfall [23,24]. In an
ttempt to balance societal concerns regarding SOI and FI [5], pro-
ortional shortfall (PS) was introduced in the Netherlands as an
quity approach that combines aspects of SOI and FI [3,5]. Although
onsensus about the application of PS has not yet been reached [25],
he approach received considerable support from politicians and
olicy makers and was incorporated into the assessment phase of
ealthcare priority setting in the Netherlands [1,3]. As such, the
etherlands is one of the ﬁrst countries to explicate the equity
riterion in this context [3,5].
This study describes the history and application of PS in the
etherlands and examines the theoretical and empirical support
or PS as well as its current role in healthcare decision making in
he Netherlands by reviewing the international PS literature and
ublicly accessible meeting reports from the Dutch appraisal com-
ittee, the Adviescommissie Pakket (ACP). Although this study
rimarily focuses on healthcare priority setting in the Netherlands,
he results of the study may  also be useful for other countries seek-
ng to operationalise the equity-efﬁciency trade-off for informing
llocation decisions in healthcare.
. A brief history of healthcare priority setting in the
etherlands
The report “Choices in health care” that was presented by the
unning Committee in 1991 [26] was a landmark publication on
ealthcare priority setting in the Netherlands. In this report, four
riteria for priority setting were formulated: necessity, effective-
ess and efﬁciency of care, and patients’ individual responsibility
or (paying for) care. In this report, the Dunning Committee used
he metaphor of a funnel to describe a criteria-based decision
odel for evaluating the composition of the publicly funded health-Please cite this article in press as: Reckers-Droog VT, et al. Looking back
in healthcare priority setting in the Netherlands. Health Policy (2018)
nsurance package. Based on this hierarchical model, technologies
hat (would subsequently) pass all criteria were to be included in
he basic beneﬁts package. The report was pivotal for the discus-
ion on priority setting, and in the following years, the criteria PRESS
 Policy xxx (2018) xxx–xxx
were put into practice [2,6,27]. The Dutch Health Care Institute
(ZiN) later reformulated these criteria as necessity of care, effective-
ness, cost-effectiveness, and necessity of insurance, respectively,
and supplemented these with a feasibility criterion [1,28].
Although none of the criteria were deﬁned and operationalised
without dispute, this proved to be particularly difﬁcult for the
necessity of care criterion [2,29]. The Dunning Committee deﬁned
necessity of care as care that is necessary for the prevention of
premature death and/or for patients who—due to some disease or
condition—cannot function normally in society [2,26]. The latter
part of this deﬁnition was regarded as problematic, as it was  unclear
how to interpret and quantify ‘normal’ functioning. Moreover, the
term ‘necessity’ implied an absolute rather than a relative cut-off
point for decision making, which was ampliﬁed by the Dunning
Committee’s use of a funnel metaphor [2,26]. If a technology failed
to pass ‘the sieve of necessity’, the technology would not be incor-
porated into the public health-insurance package, and assessment
of its (cost-) effectiveness and need for insurance would be super-
ﬂuous [2]. However, as the degree to which health technologies are
necessary varies, it was suggested that this criterion be regarded as
neither absolute nor isolated from the other criteria [2,30,31].
In 2001, Stolk et al. [2] proposed a decision model in which
necessity of care was  deﬁned as ‘burden of illness’ (BOI) and oper-
ationalised as a relative criterion by attaching a higher necessity
score to health technologies that target diseases with a higher BOI
level. Stolk et al. [2] described BOI as the average disease-related
loss in quality and length of life of patients, relative to the situa-
tion in which the disease had been absent and quantiﬁed BOI  in
terms of QALYs on a 0-1 scale. Furthermore, they proposed con-
necting the necessity of care and (cost-) effectiveness criteria by
attaching a higher societal willingness to pay (WTP) per QALY
gained to a higher level of BOI. Speciﬁcally, the authors suggested
dividing the continuous 0-1 BOI scale into seven categories and
evaluating the ICER of (new) health technologies against seven
associated monetary threshold values per QALY gained. The pro-
posed cost-effectiveness threshold values per QALY gained ranged
from approximately D 4500 to D 45,000 [32]. Deciding on the exact
cut-off points for the BOI categories, the cost-effectiveness thresh-
old range, and the shape of their reciprocal relationship were
regarded as matters of political and societal concern.
The proposed model received broad support as it contributed
to the development of a transparent and coherent decision model
for healthcare priority setting in the Netherlands by explicitly con-
necting the criteria formulated by the Dunning Committee and
enabling a uniform and systematic quantiﬁcation of BOI across
patient groups and disease areas [23,27–29]. Between 2002 and
2005, BOI was  further formalised as proportional shortfall (PS) and
deﬁned as a principle that is based on the normative standpoint
that priority in healthcare should be given to those who, due to
some disease and if left untreated, lose the largest proportion of
their QALY expectancy in absence of the disease [5,32,33]. PS is
measured on a scale from 0 (no QALY loss) to 1 (complete loss of
remaining QALY, i.e. immediate death), by applying:
PS = Disease-related QALY loss
Remaining QALY expectation in absence of the disease
(1)
For example, a disease that results in the loss of 30 out of 60
remaining QALYs has a PS level of 0.5 (30/60), and a disease that
results in the loss of 60 out of 80 remaining QALYs has a PS level
of 0.75 (60/80). The remaining QALY expectation in absence of the
disease can be calculated from age- and gender-speciﬁc mortality
data [25]. Eq. (1) can be rewritten as: and moving forward: On the application of proportional shortfall
, https://doi.org/10.1016/j.healthpol.2018.04.001
PS = 1 − Expected QALYs without treatment
Remaining QALY expectation in absence of the disease
(2)
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Table  1
Maximum reference values (in D ) per QALY gained [25].
Burden of illness Maximum reference value per QALY gained
0.10–0.40 D 20,000
0.41–0.70 D 50,000
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in the Netherlands and internationally).0.71–1.00 D 80,000
Applying Eq. (2) to the previous example, the PS level of 0.5 is
alculated as 1 – (30/60), and the PS level of 0.75 is calculated as 1 –
20/80). PS can also be calculated by using the number of expected
ALYs ‘with current treatment’ rather than ‘without treatment’ in
he equations [34]. This may  be a more logical calculation of PS
s it arguably uses a more relevant comparator and hence agrees
ith the economic-evaluation methodology. However, it should be
oted that calculating PS relative to the current treatment will likely
ead to a different, speciﬁcally lower, PS level for the same beneﬁ-
iaries and (new) health technologies. Consequently, the outcome
f a reimbursement decision that is informed by a PS level that is
alculated relative to the current treatment may  be different for
he same beneﬁciaries and (new) health technologies than when
he decision is informed by a PS level that is calculated relative to
aving no treatment. The debate on the preferred comparator is
ikely to continue in the coming period.
While consensus concerning the deﬁnition and operational-
sation of BOI gradually increased, its exact categories and the
ssociated cost-effectiveness threshold range remained a subject
f discussion for some time. In 2006, the Council for Public Health
nd Society (RVZ) suggested a continuous, upward-sloping curve
ith a maximum reimbursement of D 80,000/QALY [29]. This ﬁg-
re was substantiated by the World Health Organisation (WHO)
ule of thumb that less than three times the GDP per capita per
isability-adjusted life-year (DALY) averted indicated good value
or money for a health technology [35], by the ﬁnding that most
eimbursed health technologies in the UK had an ICER of approx-
mately D 79,000/QALY [36], and by estimations of the value of a
tatistical life [37,38]. Although the ﬁgure of D 80,000/QALY may
ave been set somewhat arbitrarily, it was considered “reasonable”
29,39]. Moreover, even though D 80,000/QALY was not ofﬁcially
dopted as the threshold value at that time, it was inﬂuential and
rovided the basis for ZiN to set three BOI categories with a maxi-
um  reimbursement of D 80,000/QALY for the highest BOI category
n 2015 [25]. Table 1 presents these three BOI categories and the
ssociated monetary reference values and shows that a higher WTP
er QALY gained, i.e. a higher necessity score, is attached to health
echnologies that target diseases with a higher BOI level [2,25].
or example, the ICER of a health technology that targets a dis-
ase with a PS level of 0.5 is evaluated against a reference value of
 50,000/QALY, while the ICER of a health technology that targets
 disease with a PS level of 0.75 is evaluated against a reference
alue of D 80,000/QALY. A health technology that targets a disease
ith a PS level below 0.1, in principle, not considered for reim-
ursement. Hence, this category is not included in the table [25,29].
hether it is feasible, in practice, to not reimburse a health tech-
ology that targets a disease with a low PS level remains doubtful
40]. For example, episodic illnesses like migraine may  not lead to
 high average PS, but do represent substantial shortfall during the
pisode.
Given the maximum reimbursement of D 80,000/QALY for the
ighest BOI category and the intention to associate increasing lev-
ls of BOI with increasing monetary reference values, ZiN set the
wo lower thresholds at D 20,000 and D 50,000 per QALY. TogetherPlease cite this article in press as: Reckers-Droog VT, et al. Looking back
in healthcare priority setting in the Netherlands. Health Policy (2018)
hese may  be seen as forming a logical set of values, given the end-
oint of D 80,000/QALY in relation to the highest BOI. In relation to
he other two values, ZiN also referred to the threshold value that is PRESS
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applied to national immunisation and preventive care programmes
in the Netherlands (D 20,000/QALY threshold) and to a Dutch study
on the societal WTP  per QALY gained ‘in others’ (D 50,000/QALY)
[25,35]. ZiN advised reassessing the reference values every ﬁve to
ten years [25] and to not use them as strict cut-off values, but
rather as references for the Dutch government when conducting
price negotiations with pharmaceutical companies and for the ACP
when recommending incorporation of health technologies into the
public health-insurance package.
The model, in which BOI is quantiﬁed and the ICERs of health
technologies are evaluated against associated reference values,
enables a transparent and coherent decision-making framework.
Given that this model is increasingly applied in the Netherlands, the
question arises whether there actually is sufﬁcient support for the
operationalisation of BOI in terms of PS to explicate the equity cri-
terion. In the next two sections we  will discuss the theoretical and
empirical support for using PS to inform priority setting in health-
care. In the subsequent section we  will review the current role of
PS in healthcare decision making in the Netherlands.
3. Is there theoretical support for proportional shortfall?
In order to optimally allocate healthcare resources for society,
it has been advocated that societal concerns regarding equity be
incorporated in the decision-making framework [10–12]. How-
ever, what society considers to be equitable and fair for priority
setting is a normative question that different people in different
contexts may  answer differently. Hence, when operationalising
the equity-efﬁciency trade-off, an additional trade-off between
different societal concerns regarding equity must be made. Con-
sequently, increasing equality in the distribution of health(care)
by applying one equity approach may  lead to increasing inequality
in the context of applying another [3,41]. It has also been argued
that, when operationalising the equity–efﬁciency trade-off, differ-
ent operationalisations are bound to face corresponding difﬁculties
[3,16]. For example, in the context of curative healthcare, ques-
tions may  arise concerning the handling of episodic diseases and
the quantiﬁcation of related health beneﬁts [3,16]. In the context
of preventive healthcare, questions may  arise concerning the group
of beneﬁciaries and the timeframe that is regarded as relevant for
estimating health beneﬁts [3,16,18]. For example, should PS be
calculated for all treated persons or only those for whom the ill-
ness was prevented? And should PS be calculated from the time
of the preventive treatment or from the time the prevented illness
would otherwise have occurred? Such choices can have a profound
effect on the outcomes of PS calculations [42]. Other questions may,
for example, arise concerning the use of age- and gender-speciﬁc
mortality data as a reference point or threshold for calculating PS
[20,43,44]. The use of such different reference points for differ-
ent (age and gender) groups implies that there is not one age or
health expectancy that would serve as a normative reference level
for all groups. Hence, this could be regarded as including some
inequ(al)ities in the calculation of PS [20]. These issues illustrate
that not only is the choice of an equity approach normative, but
additional normative choices must be made when applying the
chosen equity approach in practice [3]. Inevitably, these choices
have a large impact on PS calculations and therefore may  have
distributional consequences [3,18]. Although some initial choices
were made when operationalising PS in the Netherlands [1,2,31], it
should be noted that the discussion about how best to solve these
issues is ongoing (both in the context of healthcare priority setting and moving forward: On the application of proportional shortfall
, https://doi.org/10.1016/j.healthpol.2018.04.001
SOI and FI are two  renowned equity approaches that are based
on different normative arguments regarding whom is considered
worse off in terms of health [3,19]. As described earlier, SOI com-
ARTICLE IN PRESSG ModelHEAP-3885; No. of Pages 9
4 V.T. Reckers-Droog et al. / Health Policy xxx (2018) xxx–xxx
Table  2
Empirical evidence for support of proportional shortfall (published 2001–2017).
Study Year Country Design Mode of administration N Sample Support for PSa
Stolk et al. [33] 2005 NL Ranking exercise Web-based survey 65 Convenience ++
Olsen  [50]b 2013 Norway Pairwise-choice task Web-based survey 503 General public (age and gender) −−
Brazier et al. [51] 2013 UK DCE Web-based survey 3669 General public (age and gender) −−/−
Van  de Wetering et al. [53] 2015 NL DCE Web-based survey 1205 General public (age, gender, and education level) −−
Bobinac et al. [54] 2015 NL WTP  Web-based survey 1320 General public (age, gender, and education level) −
Rowen et al. [52]c 2016 UK DCE Web-based survey 3669 General public (age and gender) +
Richardson et al. [55]b 2017 Australia CSPC task Web-based survey 606 General public (age) +
Notes: CSPC = constant sum paired comparison; DCE = discrete choice experiment; WTP  = willingness-to-pay study; PS = proportional shortfall.
a Level of support for PS indicated by −− = no, − = limited, + = modest, ++ = strong.
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only aims to equalise health beneﬁts in terms of current and
rospective health, and FI aims to do so in terms of lifetime health
3,10,11,19]. As such, FI is consistent with the notion that, all else
qual, younger people should be prioritised over older people as
hey have not yet enjoyed a fair share of lifetime health [5,11]. It
hould be noted that the role of age is merely indirect in the FI
pproach as it is applied as a proxy for lifetime health [20,43,44].
ndeed, in the FI approach, age itself is not regarded as a morally
elevant argument for priority setting [44].
PS does not originate from a unique theory about distributive
ustice but was developed as an equity approach that combines
spects of SOI and FI by prioritising those who are worse off in
erms of a lower amount of prospective and lifetime health [3,5].
hile SOI and FI aim to equalise absolute health beneﬁts, PS aims
o equalise relative beneﬁts between persons with respect to their
otential for health [5,33]. It has been argued that PS balances soci-
tal concerns regarding SOI and FI and treats the two approaches
s equally important [5]. However, PS is calculated as the fraction
f disease-related QALY loss relative to the remaining QALY expec-
ation in absence of the disease rather than to the lifetime-QALY
xpectation from birth. Various authors have discussed the relative
ature of PS and the theoretical and empirical relevance of using
 lifetime perspective for informing allocation decisions in health-
are [20,24,45–47]. Here, we would like to point out that PS may
e viewed as placing more emphasis on relative prospective-health
oss, i.e. the SOI component of PS, than on relative lifetime-health
oss, i.e. the FI component of PS. This is illustrated by the fact that PS
oes not, by deﬁnition, discriminate between people with different
evels of ‘enjoyed’ lifetime health as healthcare beneﬁciaries of all
ges could potentially experience the same level of PS. For exam-
le, in the case of immediate death, healthcare beneﬁciaries who
re 10 and 80 years old are given the same weight in the distribu-
ion of healthcare, as both will have a PS level of 1. However, when
he same beneﬁciaries lose two of their remaining QALYs, more
eight will be given to the 80 year olds, as their PS level will be
igher than that of the 10 year olds. Indeed, in allocation decisions,
S may  more frequently give a higher weight to older patients than
he FI approach would. Stolk et al. [5] argued that the FI approach
discriminates against the elderly more strongly than policy mak-
rs seem to prefer” and that PS could mitigate the ageism that is
mplied by the FI approach. It was, therefore, hypothesised that PS
ight be better aligned with distributional preferences of health
olicy makers. Should this hypothesis not be supported by empir-
cal evidence, the authors suggested to add age weights and adjust
S for age-related preferences
A strength of PS, which it shares with the SOI and FI approaches,
ies in its quantiﬁcation of health losses in terms of QALYs. ThisPlease cite this article in press as: Reckers-Droog VT, et al. Looking back
in healthcare priority setting in the Netherlands. Health Policy (2018)
nables the application of PS across disease areas and patient
opulations. However, this strength comes with a limitation as
reatment beneﬁts beyond health and health-related quality of life
QOL) that may  not be captured by the QALY are increasingly recog-ences for length of life.
nised as being relevant [48]. Therefore, the current application of
PS, i.e. its quantiﬁcation in terms of QALYs, may  be regarded as
appropriate for informing decisions concerning curative and pre-
ventive treatments but less so for decisions concerning treatments
that focus on broader beneﬁts, for example related to wellbeing
[49]. If the aim is to generate social welfare from the public health-
insurance package, the application of an equity approach that is
uniformly applicable and hence that models information concern-
ing health, QOL, and broader wellbeing could be preferable for
informing decisions concerning all healthcare sectors. We  stress
that this limitation should not be attributed to PS (or to FI or SOI)
as a principle but rather to the way in which PS is currently quanti-
ﬁed and applied in decision-making practice. In fact, PS does enable
a uniform decision model for priority setting across all healthcare
sectors, as the QALY in the PS equation can be replaced with—or
complemented by—any other (generic) outcome measure of choice.
4. Is there empirical support for proportional shortfall?
We  examined empirical support for PS by reviewing the inter-
national literature on PS in the context of healthcare priority
setting. We used the search terms “proportional shortfall”, “prefer-
ence”, “elicitation”, “priority setting”, and “health” or “healthcare”
in Google Scholar. The search was  performed on October 16, 2017
and supplemented with a hand search. We restricted the search to
articles written in English or Dutch, published between 2001, i.e.
the year in which PS was introduced in the Netherlands, and 2017,
and of which the full text was available. Articles were selected for
review if the aim of the study was to elicit preferences for PS rela-
tive to either preferences for no equity weighting or for weighting
on the basis of another equity approach, such as SOI and/or FI. Our
search resulted in 205 studies, in seven of which preferences for PS
were elicited. Table 2 presents an overview of these seven studies
and their results.
Stolk et al. [33] compared support for SOI, FI, and PS by asking
respondents to assign a priority rank to the treatment of ten health
conditions. Stolk et al. found strong evidence for PS being consistent
with social preferences for healthcare priority setting. Although
preferences for PS dominated preferences for SOI, stronger support
was found for FI. The authors obtained these results using a small
convenience sample in the Netherlands that consisted of health
policy makers, researchers, and students. Consequently, the results
may  be prone to bias, e.g. due to respondents sharing common
opinions.
Olsen [50] examined support for PS in a sample that was
representative, in terms of age and gender, of the general adult and moving forward: On the application of proportional shortfall
, https://doi.org/10.1016/j.healthpol.2018.04.001
population in Norway in terms of age and gender. Olsen applied a
pairwise-choice task and asked respondents to prioritise patients
based on their age, remaining lifetime health without treatment,
and increase in remaining lifetime health with treatment. Olsen
 IN PRESSG ModelH
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Table 3
Search terms used for reviewing ACP meeting reports.
Domain Search term
Priority-setting criteria Necessity of care
Necessity of insurance
Effectiveness; Effect
Cost-effectiveness; Efﬁciency
Feasibility
Equity considerations Severity of illness
Fair innings
Burden of illness
Absolute shortfall
Proportional shortfall
Treatment beneﬁts Therapeutic outcome; Therapeutic value
(Health-related) quality of life
Quality-adjusted life-year; QALY
Wellbeing
Capability
Life satisfaction
Patient characteristics Age
Socio-economic status; SES
Lifestyle
Culpability; Individual responsibility
Reference value(s)ARTICLEEAP-3885; No. of Pages 9
V.T. Reckers-Droog et al. / H
ound strong support for the FI approach; however, he found no
upport for PS.
Brazier et al. [51] examined support for BOI operationalised in
erms of PS in a sample that was representative of the general
opulation in the UK in terms of age and gender by performing
 web-based discrete choice experiment (DCE). Their main results
id not support PS. However, when respondents who seemingly
isunderstood the DCE task were excluded, some support for PS
as found.
Rowen et al. [52] used the data from Brazier et al. [51] to examine
upport for PS by applying the number of expected QALYs ‘with cur-
ent treatment’ rather than ‘without treatment’ in the PS equation.
owen et al. concluded that, although the results were not robust
gainst different versions of the DCE survey, there was some mod-
st support for BOI operationalised in terms of PS relative to the
urrent treatment.
Van de Wetering et al. [53] examined support for PS in a sam-
le that was representative of the general adult population in
he Netherlands in terms of age, gender, and education level by
onducting a web-based DCE. They found substantial preference
eterogeneity and some counterintuitive results, as respondents
ere less likely to prioritise patients with higher levels of PS.
Bobinac et al. [54] examined societal WTP  for QALY gains in
atients with different levels of PS in a sample that was represen-
ative of the general adult population in the Netherlands in terms
f age, gender, and education level by conducting a web-based sur-
ey. They found occasional support for PS as a predictor of the
TP  for QALY gains. Some support for PS was found when QALY
ains were relatively small. However, the level of support decreased
hen QALY gains increased in size. In addition, support for PS was
enerally dominated by concerns for the (younger) age of patients.
Richardson et al. [55] examined support for PS in a sample that
as close to being representative of the general adult population in
ustralia in terms of age. They applied constant-sum paired com-
arison tasks and asked respondents to prioritise patients based on
heir gain in life years due to treatment, age, years to death with-
ut treatment, and age at death with and without treatment. Their
tudy found some support for PS; however, found that concerns
or PS were dominated by concerns for the (individual) SOI and FI
pproaches. Richardson et al. further found that PS insufﬁciently
eﬂects respondents’ age-related preferences.
Although each of these studies examined societal support by
liciting preferences for PS, it is important to note that the studies
iffer with respect to the samples, methods, additionally included
ariables, and/or equity approaches. In addition, Olsen [50] and
ichardson et al. [55] examined preferences for equity in the con-
ext of length of life, and hence did not present PS in terms of
roportional QALY shortfall. Consequently, a direct comparison of
he results presented in Table 2 is not possible.
. What is the role of proportional shortfall in healthcare
ecision making?
The necessity (of care and of insurance), effectiveness, cost-
ffectiveness, and feasibility criteria are addressed and quantiﬁed
n the assessment phase of healthcare decision making in the
etherlands and subsequently assessed on social and ethical
rounds in the appraisal phase. If the operationalisation of BOI in
erms of PS is considered suboptimal for explicating the equity cri-
erion, it seems reasonable to expect that this would be explicitly
iscussed during meetings of the ACP appraisal committee.Please cite this article in press as: Reckers-Droog VT, et al. Looking back
in healthcare priority setting in the Netherlands. Health Policy (2018)
To examine the current role of PS in the appraisal phase of
ealthcare decision in the Netherlands, we conducted a review
f publicly accessible ACP meeting reports that were published
etween January 1, 2013 and December 31, 2016. The reportsReference values
(Monetary) threshold
include agendas, minutes, and documents, including decision
reports and draft ZiN reports that were discussed by the ACP. Table 3
presents the terms (and their domains) addressing healthcare pri-
ority setting that we used for searching the reports (in the Dutch
language, but translated here for clarity). Reports that did not allow
a digital search, including ACP reports that were published before
January 1, 2013, were excluded from the review, as were search
terms that occurred in the names of health organisations and gov-
ernment ministries. Draft versions of minutes were included only
if ﬁnal minutes were not published.
Between 2013 and 2016, 179 ACP reports were published of
which two were excluded for not allowing a digital search. Table 4
presents the frequency with which the search terms were iden-
tiﬁed in the remaining 177 reports. The necessity of care and of
insurance, effectiveness, cost-effectiveness (including the search
term efﬁciency), and feasibility criteria were identiﬁed 1680, 495,
8700, 4423, and 236 times, respectively. The effectiveness criterion
was most frequently found, followed by the cost-effectiveness and
necessity of care criteria. The necessity of insurance and feasibility
criteria were identiﬁed less frequently.
PS was identiﬁed 14 times in a total of six reports, four of which
discussed the operationalisation of BOI in terms of PS. In a report
from 2013, ZiN described the deﬁnition and calculation of PS. In this
report, ZiN stated that “PS was  developed at a time when ageism
was an important issue in the allocation of healthcare resources”
and that “therefore BOI is calculated in proportion to life expecta-
tion, which ensures that PS does not distinguish between younger
and older people”. However, ZiN also stated that “recently, there
are increasing indications that people do discriminate between
age groups” and that people “value health gains in younger peo-
ple more than in older people”, which “argues against PS and the
rule of rescue, and in favour of FI”. In the accompanying minutes,
an ACP member stated that “the passage about BOI is still not in
agreement with what was  discussed in previous meetings” and
that s/he “understand[s] that applying the capability approach is
out of reach”, but that s/he “would like to see the denominator
removed from the presented deﬁnition of PS”. In a report from
2015, ZiN stated that “because we  have not yet reached consensus
about the quantiﬁcation of BOI, we  will temporarily [. . .]  quantify and moving forward: On the application of proportional shortfall
, https://doi.org/10.1016/j.healthpol.2018.04.001
BOI in terms of DALYs”. In this report, ZiN additionally stated that
“priority will be given to solving this issue” and that “a report on
the quantiﬁcation of BOI will be issued this summer”. In a later
Please cite this article in press as: Reckers-Droog VT, et al. Looking back
in healthcare priority setting in the Netherlands. Health Policy (2018)
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report from 2015, ZiN stated that “the next coming months will be
used to see how to better align the equity criterion PS with current
social preferences”. According to the accompanying minutes, these
statements by ZiN were not discussed by ACP members.
The reference of one of the ACP members to Sen’s capability
approach [41] may  indicate a preference for quantifying health
beneﬁts in terms of broader wellbeing, as for example is done by
applying the ICECAP measure [56]. Wellbeing, including the terms
capability and life satisfaction, was  identiﬁed 93 times in 29 reports
from 2013 onwards, among which the capability approach was
identiﬁed 15 times in ﬁve reports (not in Table 4). In these reports,
the capability approach was discussed as an alternative to quanti-
fying health beneﬁts in terms of QALYs. In a report from 2013, ZiN
stated that “a recent discussion involves the question of whether
the capability approach is better aligned with the social basis that
underlies managing the public health-insurance package” and that
“applying this approach may  be more appropriate for healthcare
sectors where ‘health gains’ are not the primary objective, such as
long-term care and mental healthcare”. The same report stated that
“changing the desired outcome of healthcare does not answer the
question of when care is more necessary for one person than for
another” and that “the capabilities approach can also be applied
to calculate lifetime capabilities (fair innings), prospective capa-
bilities, or the relative loss of capabilities (proportional shortfall)”,
and so “applying the capability approach will not solve the issue of
prioritisation in healthcare”.
The ACP member’s request to remove the denominator from
the PS equation may  indicate a preference for operationalising
the equity criterion in terms of absolute shortfall (AS) rather than
proportional shortfall, and this may  in turn indicate a prefer-
ence regarding FI, age, and reducing lifetime-health inequalities
[23,50]. AS was  not identiﬁed in any of the ACP reports and the FI
approach was  identiﬁed 11 times in four reports. In contrast, the
SOI approach was identiﬁed 0 times. However, concerns for SOI that
were expressed through concerns for prospective-health loss, the
rule of rescue, and for the severity of (symptoms of) a disease or con-
dition were identiﬁed 3 times in 1 report, 5 times in 3 reports, and
2614 in 92 reports, respectively (not in table). Age was  identiﬁed
895 times in 79 reports. Regarding age and other patient charac-
teristics, age was  identiﬁed 16.6 and 2.3 times more frequently
than SES and lifestyle (including the search terms culpability and
individual responsibility), respectively.
Although the operationalisation of BOI in terms of PS was  occa-
sionally discussed in some reports, and in one report from 2014
an ACP member stated that “BOI cannot be quantiﬁed in numeric
terms in this speciﬁc situation”, the application of BOI itself was
not discussed. BOI was  identiﬁed 672 times in 68 reports, and from
2015 onwards, increasingly related to the corresponding reference
values (presented in Table 1), which were identiﬁed 328 times in
26 reports. In 2013, BOI was  most frequently expressed in qualita-
tive terms, e.g. in terms of “low” or “high” BOI, and only sometimes
in numeric terms, by disability weights used for calculating DALYs.
From 2014 onwards, BOI was  less frequently expressed in qualita-
tive terms and was mostly quantiﬁed by disability weights or the
number of DALYs lost, which at times were presented alongside the
mean life expectancy of patients with and without the disease. In
three reports, BOI was  addressed as a relative measure; however,
the presented disability weights or DALYs lost were not applied as
such. From 2015 onwards, BOI was  most frequently quantiﬁed in
terms of PS, in a total of seven reports. In four of these reports, PS
calculations were presented alongside disability weights, number
of DALYs lost, mean life expectancy, or years of life lost calculations. and moving forward: On the application of proportional shortfall
, https://doi.org/10.1016/j.healthpol.2018.04.001
Based on these results, it appears that the application of BOI
was not publicly discussed by ACP members between 2013 and
2016. The operationalisation of BOI in terms of PS, and the role
of PS in healthcare decision making, was infrequently discussed.
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hile BOI was most frequently expressed qualitatively in 2013, it
as increasingly quantiﬁed in later years, usually in terms of dis-
bility weights or the number of DALYs lost. From 2015 onwards,
CERs were increasingly related to the monetary reference values
er QALY gained that were set by ZiN that year [25] and BOI was
ost frequently quantiﬁed in terms of PS. In this context, it needs
oting that there was a change in ACP members in 2015 and this
ay  have contributed to the increased application of PS from then
n. In the reports, PS calculations were frequently presented along-
ide disability weights, number of DALY lost, life expectancy, and
ears of life loss calculations. This variety may  reﬂect that there is no
onsensus (yet) about the application of PS in healthcare decision
aking in the Netherlands.
. Discussion
The importance of operationalising the equity-efﬁciency trade-
ff for informing priority setting in healthcare is increasingly
ecognised. This study described the history and application of PS in
he Netherlands, examined the theoretical and empirical support
or PS as an operationalisation of the equity-efﬁciency trade-off,
nd looked into the current role of PS in healthcare decision making.
Overall, our results indicate general support for the decision
odel in which BOI is quantiﬁed and the ICERs of health technolo-
ies are evaluated against the reference values per QALY gained
et by ZiN. This model connects the criteria for healthcare decision
aking that were previously formulated by the Dunning Commit-
ee and enables a uniform decision model for priority setting across
ll healthcare sectors. Consequently, the model has received broad
upport in research and policy circles and has been incorporated
nto the healthcare decision-making framework in the Netherlands.
Although the model is increasingly applied in decision-making
ractice, the results of our literature review suggest that theoreti-
al support for PS is moderate at best. In applying PS, a trade-off
etween the SOI and FI approaches is made and, consequently,
ocietal preferences for either of the two equity approaches may
e insufﬁciently reﬂected when allocating resources in health-
are. However, this may  be regarded as a general limitation that
omes with applying any equity approach in practice, as improving
quality in the distribution of health(care) by applying one equity
pproach may  inevitably be associated with increasing inequal-
ty in the context of applying another [3]. A limitation that is not
estricted, but may  be more speciﬁc, to applying PS, is that it miti-
ates ageism between patient groups, as beneﬁciaries of all ages can
xperience the same level of PS. The results of our study suggest that
his may  inadequately reﬂect societal preferences relating to age
nd reducing lifetime-health inequalities between patient groups.
lthough the results of our literature review suggest that empiri-
al support for PS is limited, it should be noted that that empirical
vidence regarding PS so far is scarce and inconclusive, so that a
ejection of the PS approach can also not be concluded. The societal
oncern regarding age that is currently insufﬁciently reﬂected by
S could be incorporated by adjusting PS for age. However, there
s no empirical evidence (to date) to support the hypothesis that
his would better align with societal preferences and hence future
esearch on this topic will be necessary. The results of our review of
ublicly accessible ACP reports suggest that the ACP did not publicly
iscuss the deﬁnition and operationalisation of necessity of care in
erms of BOI between 2013 and 2016. In fact, BOI became increas-
ngly quantiﬁed, and ICERs were increasingly evaluated against the
eference values per QALY gained set by ZiN in 2015. The opera-Please cite this article in press as: Reckers-Droog VT, et al. Looking back
in healthcare priority setting in the Netherlands. Health Policy (2018)
ionalisation of BOI in terms of PS was publicly discussed by the
CP, although only on rare occasions. This may  indicate that the
CP supports the operationalisation of BOI in terms of PS. However,
he variety of BOI quantiﬁcations in ACP reports demonstrates that PRESS
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consensus about the operationalisation and quantiﬁcation of BOI
has not yet been reached.
Relatively few studies have examined the theoretical and empir-
ical support for PS, and to our knowledge, no other study has
examined the current role of PS in healthcare decision making in
the Netherlands. Although this limits our ability to compare our
results with those of others, we  would like to compare the results
of our empirical literature review to the results of a study conducted
by Nord and Johansen [57] and the public consultation of NICE on
the valued-based assessment of health technologies [58–60]. Nord
and Johansen [57] examined support for PS, relative to preferences
for no other equity approach, by conducting an empirical literature
review that built on an earlier review by Shah [61] and included
20 preference studies that were conducted in nine different coun-
tries between 1991 and 2011. Under the assumption of a stable
health condition and no loss in length of life for patients, Nord and
Johansen found strong support for PS, although the strength of the
support varied greatly between the included studies. Regarding the
inclusion criteria for our literature review, ﬁve of the studies that
Nord and Johansen included were conducted after the introduc-
tion of PS in the Netherlands. Of these ﬁve studies, two quantiﬁed
health beneﬁts in terms of QOL and three in terms of QALYs. How-
ever, none of the three latter studies elicited preferences for PS
and, as such, were not included in our literature review. Although
the results of our review seem to be discordant with Nord and
Johansen’s results, and it is worth mentioning that in two  of the
ﬁve aforementioned studies the public was found to be less likely
to prioritise patients with higher levels of SOI [45,62], a direct com-
parison of results is not possible for reasons that are previously
described.
NICE conducted a public consultation in the UK in 2014 on the
topic of value-based assessment of health technologies [58–60].
NICE asked the public, including patients, economists, academics,
and members of the pharmaceutical industry, ten related questions.
One of the questions concerned the extent to which the public
regarded PS as an appropriate approach for quantifying BOI [58].
NICE received reactions from 121 individuals and organisations,
but no general agreement emerged [59]. In summary, the public
regarded PS as a measure that is feasible and suitable for calculat-
ing BOI in terms of health and QOL impact in cases where a disease
affects older patients. However, as in the ACP, there were concerns
about PS not being a suitable measure for capturing broader aspects
of BOI that are not included in the QALY. In addition, there were
concerns about PS assigning a lower weight to the BOI of younger
patients than to older patients due to differences in the PS denomi-
nator, i.e. the remaining QALY expectation in absence of the disease.
More generally, there were concerns about the strong reliance on
the QALY in health technology assessment and in the calculation of
BOI, resulting in a possible double counting of beneﬁts when set-
ting priorities in healthcare [59]. Because of the lack of agreement
that emerged from the public consultation, NICE decided to not
change their current health-technology appraisal and end-of-life
guidelines [60].
Some limitations of our study must be mentioned. A ﬁrst limi-
tation concerns the lack of a systematic review of the studies that
we used to examine the theoretical and empirical support for PS.
However, as the number of studies examining PS is limited, we
believe that our review was  comprehensive and that our results
were not inﬂuenced by the lack of a systematic search. A second
limitation concerns the use of publicly accessible ACP reports to
examine the current role of PS in healthcare decision making in the
Netherlands. In addition to public meetings, the ACP held closed and moving forward: On the application of proportional shortfall
, https://doi.org/10.1016/j.healthpol.2018.04.001
meetings between 2013 and 2016, and the role of PS may have been
discussed more frequently in these. However, the reports of these
closed meetings are not publicly accessible and therefore could not
be included in our review of ACP reports. Although the role of PS
 ING ModelH
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ay  have been discussed more frequently during closed meetings,
nd the inclusion of closed meeting reports might have changed the
eview results, it seems reasonable to expect that any discussion of
S in a closed meeting would have been reﬂected in a public meet-
ng where the decision making actually took place. A ﬁnal limitation
oncerns the risk of double counting search terms due to a possible
verlap in ACP meeting reports. This risk was reduced by excluding
oncept versions of minutes unless a ﬁnal version was not available;
owever, this distinction could not always be made for meeting
ocuments. For example, documents concerning the reimburse-
ent of a speciﬁc treatment may  have been discussed at more than
ne ACP meeting. As a result, a higher relative importance may  have
een assigned to some of the search terms. However, as the main
bjective of our review of ACP reports was to examine the role of
S in healthcare decision making, and PS was infrequently iden-
iﬁed, we believe that the inﬂuence of possible double counting
n conclusions drawn from the review is limited. Concerning the
requency with which the search terms were identiﬁed in the ACP
eeting reports, we would like to additionally point out that these
requencies should be considered in the broader context of prior-
ty setting in the Netherlands. This broader context determines the
genda and the priorities that are set in ACP meetings and hence
nﬂuences the frequency with which the search terms were identi-
ed. Apart from these limitations, we consider it a strength of our
tudy that we have examined support for PS at three different lev-
ls, i.e. at a theoretical, empirical, and decision-making level. To our
nowledge, this is the ﬁrst study to examine support for PS in such
n extensive manner.
Ideally, the operationalisation of the equity-efﬁciency trade-off
re normatively justiﬁable and empirically supported. The various
ormative choices that need to be made in this context indicate that
 trade-off or a compromise between different societal concerns
egarding equity and fairness needs to be made. Consequently, the
perfect’ explication of the equity criterion may  not exist, and PS,
ike any other explication, will have its strengths and limitations.
he results of our study indicate that the decision model in which
ncreasing levels of BOI are quantiﬁed and ICERs are related to
he associated monetary reference values per QALY gained is sup-
orted and increasingly applied in decision-making practice. The
perationalisation of BOI in terms of PS enables a uniform deci-
ion model for priority setting across all healthcare sectors that
an be applied by replacing or complementing the QALY in the
S equation with a broader, wellbeing-related, generic outcome
easure such as the ICECAP [56]. The results of our study also
ndicate that PS insufﬁciently reﬂects societal preferences regard-
ng age and reducing lifetime-health inequalities between patient
roups. Future research is needed to develop and examine alter-
ative versions of PS, such as a version of PS that is adjusted for
ellbeing- and age-related preferences. These could be compared
o the current operationalisation of PS, also in terms of alignment
ith general public preferences. There are different possibilities for
ombining PS and age in a preference-elicitation study. For exam-
le, it may  be interesting to elicit preferences for a PS version in
hich the denominator of the PS equation consists of patients’
ifetime-QALY expectation. It may  also be interesting to elicit pref-
rences for combinations of PS and lifetime health (or age). For
his, a matrix combining different age and PS classes could be used.
o increase comparability between studies, we recommend using
 more standardised approach to eliciting equity weights. Related
o this, we would like to mention that the variety of the ways in
hich BOI is quantiﬁed in ACP reports may, understandably, reﬂect
he present lack of consensus about the application of PS. However,Please cite this article in press as: Reckers-Droog VT, et al. Looking back
in healthcare priority setting in the Netherlands. Health Policy (2018)
his variety is in itself undesirable as it hampers the transparency
nd comparability of BOI quantiﬁcations for different beneﬁciaries
nd, subsequently, of the relevant cost-effectiveness threshold of
new) health technologies in the Netherlands. ZiN is expected to
[ PRESS
 Policy xxx (2018) xxx–xxx
publish a report on the standardisation of the BOI quantiﬁcation
later this year to solve this issue.
7. Conclusions
The results of this study suggest that there is support for the
decision model in which BOI is quantiﬁed and ICERs are evaluated
against increasing monetary reference values. Although consen-
sus regarding the application of PS has not yet been reached, BOI
is increasingly quantiﬁed in terms of PS in decision-making prac-
tice. As any (generic) outcome measure can be included in the PS
equation, PS enables a uniform decision model for priority set-
ting across all healthcare sectors. Empirical support for PS appears
to be limited, as PS may  insufﬁciently reﬂect societal preferences
regarding age and reducing lifetime-health inequalities. Hence,
further investigation into the reﬁnement of PS—or exploration
of another approach—appears warranted for operationalising the
equity-efﬁciency trade-off in healthcare priority setting.
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